Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection

DJ Hausenloy, HE Bøtker, P Ferdinandy… - Cardiovascular …, 2019 - academic.oup.com
DJ Hausenloy, HE Bøtker, P Ferdinandy, G Heusch, GA Ng, A Redington, D Garcia-Dorado
Cardiovascular Research, 2019academic.oup.com
Acute myocardial infarction (AMI) and the heart failure (HF) that often complicates this
condition, are among the leading causes of death and disability worldwide. To reduce
myocardial infarct (MI) size and prevent heart failure, novel therapies are required to protect
the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). In this
regard, targeting cardiac innervation may provide a novel therapeutic strategy for
cardioprotection. A number of cardiac neural pathways mediate the beneficial effects of …
Abstract
Acute myocardial infarction (AMI) and the heart failure (HF) that often complicates this condition, are among the leading causes of death and disability worldwide. To reduce myocardial infarct (MI) size and prevent heart failure, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). In this regard, targeting cardiac innervation may provide a novel therapeutic strategy for cardioprotection. A number of cardiac neural pathways mediate the beneficial effects of cardioprotective strategies such as ischaemic preconditioning and remote ischaemic conditioning, and nerve stimulation may therefore provide a novel therapeutic strategy for cardioprotection. In this article, we provide an overview of cardiac innervation and its impact on acute myocardial IRI, the role of extrinsic and intrinsic cardiac neural pathways in cardioprotection, and highlight peripheral and central nerve stimulation as a cardioprotective strategy with therapeutic potential for reducing MI size and preventing HF following AMI. This article is part of a Cardiovascular Research Spotlight Issue entitled ‘Cardioprotection Beyond the Cardiomyocyte’, and emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.
Oxford University Press